Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15936353 | 0.88 | GCG (0.46) | GCGEPHX1SMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL1765416 | 0.77 | MEN1 (0.43) | SMN1; SMN2NPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL1765396 | 0.74 | NPC1 (0.40) | EPHX1SMN1; SMN2NPC1ALDH1A1EPHX2 | |
| SCHEMBL2655620 | 0.74 | ALDH1A1 (0.44) | SMN1; SMN2NPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL2655039 | 0.73 | MAPT (0.38) | ALDH1A1MEN1KMT2AHPGDRAB9A | |
| SCHEMBL2654692 | 0.71 | GCGR (0.47) | GCGALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL11962616 | 0.71 | DHODH (0.57) | EPHX1SMN1; SMN2NPC1ALDH1A1EPHX2 | |
| SCHEMBL3107066 | 0.70 | SMN1; SMN2 (0.44) | EPHX1SMN1; SMN2NPC1ALDH1A1EPHX2 | |
| SCHEMBL1765176 | 0.70 | DHODH (0.60) | EPHX1SMN1; SMN2NPC1ALDH1A1EPHX2 | |
| SCHEMBL5070258 | 0.70 | EPHX1 (0.56) | EPHX1SMN1; SMN2NPC1ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957068-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20090156655-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | disclosed |
| EP-1957068-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007120270-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156655-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | GCG 5/4885EPHX1 2400/4885SMN1; SMN2 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.